Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
NCT02232191Phase 2Recruiting
- Sponsor
- University of California, Davis
- Start
- Dec 2014
- Primary completion
- Jul 2027
- Countries
- 1
01
Overview
A Phase 2 trial of 23-valent pneumococcal polysaccharide vaccine in pneumococcal infection, sponsored by University of California, Davis. Started Dec 2014; status: recruiting.
02
Drugs
23-valent pneumococcal polysaccharide vaccine
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT02232191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02232191.